WO2001005366A1 - Sunscreen aerosol composition - Google Patents

Sunscreen aerosol composition Download PDF

Info

Publication number
WO2001005366A1
WO2001005366A1 PCT/US2000/019459 US0019459W WO0105366A1 WO 2001005366 A1 WO2001005366 A1 WO 2001005366A1 US 0019459 W US0019459 W US 0019459W WO 0105366 A1 WO0105366 A1 WO 0105366A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
mixtures
group
present
stabilizer
Prior art date
Application number
PCT/US2000/019459
Other languages
French (fr)
Inventor
Thomas Russo
Joseph Hourihan
James Sanogueira
Original Assignee
Playtex Products, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Playtex Products, Inc. filed Critical Playtex Products, Inc.
Priority to EP00947462A priority Critical patent/EP1200054A1/en
Priority to MXPA02000457A priority patent/MXPA02000457A/en
Priority to AU61065/00A priority patent/AU6106500A/en
Publication of WO2001005366A1 publication Critical patent/WO2001005366A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Definitions

  • the present invention relates to sunscreens. More particularly, the present invention relates to sunscreen compositions dispensed in the form of an aerosol product that foams.
  • Sunscreen compositions are applied to the skin to protect the skin from the sun's ultraviolet rays that can lead to erythema, a reddening of the skin also known as sunburn.
  • Sunlight or ultraviolet radiation in the UV-B range has a wavelength of 290nm to 320nm and is known to be the primary cause of sunburn.
  • Ultraviolet rays at a wavelength of 320nm to 400nm, known as UV-A radiation produces tanning of the skin. However, in the process of doing so, the UV-A rays can damage or harm the skin.
  • Another long-term effect is premature aging of the skin. This condition is characterized by skin that is wrinkled, cracked and has lost its elasticity.
  • sunscreens are typically formulated with the goal of inhibiting skin damage from the sun's rays.
  • the sunscreen composition filters or blocks the harmful UV-A and UV-B rays that can damage and harm the skin. It is believed that sunscreen agents accomplish this by absorbing the UV-A and/or UV-B rays.
  • sunscreen compositions are oil and water emulsions.
  • the UV-absorbing compounds are typically incorporated into the oil phase.
  • Sunscreens may also include physical or inorganic metal oxides that block the sun's rays. Titanium dioxide and zinc oxide are commonly used for this purpose.
  • SPF sun protection factor
  • a third consideration is product feel and how well the product spreads over the skin. Typically, consumers want a product that feels smooth and silky and be applied in a smooth continuous film over the skin. Another factor is the shelf life of the product, which is determined by the chemical and physical stability of the sunscreen composition.
  • product form will also play a part since there is a variety of choices such as lotions, gels, creams, sprays, and aerosols that are available. Form preference could ultimately determine whether the consumer decides to purchase the product.
  • the unique product forms can be appealing to many consumers who are looking for something different.
  • Sunscreens that are made in the form of an aerosol are not commonplace, particularly, aerosols that deliver the product as a foam.
  • the present invention in brief summary, is a sunscreen composition that is dispensed as an aerosol product.
  • the composition contains a sunscreen agent, an emulsifier, a foam builder/stabilizer, a counterion, and a propellant.
  • the sunscreen composition also contains an emollient, a humectant, a preservative/antioxidant, and water.
  • the ratio of the foam builder/stabilizer to counterion must be about 1 :4 to about 5:1.2. More preferably, the ratio is about 1 :1 to about 5:1.
  • the present invention is a sunscreen composition in the form of an aerosol comprising a sunscreen agent, an emulsifier, a foam builder/stabilizer, a counterion, and a propellant.
  • sunscreen agents that can be used in the present invention must be capable of absorbing or blocking the harmful effects of ultraviolet radiation. In addition, they must be non-toxic and non-irritating when applied to the skin. Suitable sunscreen agents include, for example, para- aminobenzoic acid (PABA), benzophenone-1 , benzophenone-2, benzophenone-3, benzophenone-4, benzophenone-6, benzophenone-8, benzophenone-12, methoxycinnamate, ethyl dihydroxypropyl-PABA, glyceryl PABA, homosalate, methyl anthranilate, octocrylene, octyl dimethyl PABA, octyl methoxycinnamate, octyl salicylate, PABA, 2- phenylbenzimidazole-5-sulphonic acid, triethanolamine salicylate, 3-(4- methylbenzylidene)-camphor, red petrolatum, and mixtures thereof.
  • PABA para-
  • the sunscreen agents may be present in an amount about 1 wt.% to about 40 wt.% of the total weight of the composition of the present invention.
  • the total amount of sunscreen agents in the composition will depend upon the sun protection factor (SPF) desired. Normally, the higher the SPF, the greater the total amount of sunscreen agents.
  • the sunscreen agents are included at about 4 wt.% to about 30 wt.%.
  • An emulsifier is an essential component of the present invention.
  • An emulsifier enables two or more immiscible liquids to be combined homogeneously, while increasing the viscosity of the composition.
  • Emulsifiers that may be used in the present invention include sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate, sorbitan trioleate, polyglyceryl-3- diisostearate, polyglycerol esters of oleic/isostearic acid, polyglyceryl-6 hexaricinolate, polyglyceryl-4-oleate, polygylceryl-4 oleate/PEG-8 propylene glycol cocoate, oleamide DEA, sodium glyceryl oleate phosphate, hydrogenated vegetable glycerides phosphate and mixtures thereof.
  • one or more synthetic polymers may be used as an emulsifier.
  • PVP Eicosene copolymer acrylat.es/C-io-C30 alkyl acrylate crosspolymer, acrylates/steareth-20 methacrylate copolymer, PEG-22/dodecyl glycol copolymer, PEG-45/dodecyl glycol copolymer, and mixtures thereof.
  • the preferred emulsifiers are PVP Eicosene copolymer, acrylates/C 10 -C 3 o alkyl acrylate crosspolymer, PEG-20 sorbitan isostearate, sorbitan isostearate, and mixtures thereof.
  • the one or more emulsifiers are present in a total amount about 0.01 wt.% to about 15 wt.% of the total weight of the composition of the present invention.
  • about 0.1 wt.% to about 3 wt.% of emulsifiers are used.
  • the composition of the present invention must include a foam builder/stabilizer.
  • the preferred foam builder/stabilizer is cetyl phosphate, DEA cetyl phosphate, TEA myristate, TEA stearate, magnesium stearate, sodium stearate, potassium laurate, potassium ricinoleate, sodium cocoate, sodium tallowate, potassium castorate, sodium oleate, and mixtures thereof.
  • the foam builder/stabilizer in an amount about 0.1 wt.% to about 5 wt.% must be added to the composition of the present invention.
  • the foam builder/stabilizer is present in an amount about 0.1 wt.% to about 3 wt.%.
  • Counterions are in the composition of the present invention to neutralize components such as an emulsifier and a foam builders/stabilizer.
  • Sodium hydroxide, potassium hydroxide, diethanolamine, triethanolamine, aminomethyl propanol, trisodium ethylenediaminetetraacetic acid, and mixtures thereof, are examples of suitable counterions used in the present invention.
  • the preferred counterion is triethanolamine.
  • Counterion is present in an amount about 0.01 wt.% to about 8 wt.% in the composition of the present invention. Preferably, counterion is present in an amount about 1 wt.% to about 5 wt.%.
  • a critical feature of the present invention is the ratio of the foam builder/stabilizer to counterion. To ensure superior foam quality and integrity, the ratio must be about 1 :4 to about 5:1.2. Preferably, the ratio is about 1 :1 to about 5:1.
  • Propellant The propellant must be capable of producing a sufficient pressure for expelling the composition from an aerosol container. Furthermore, the propellant must be non-irritating, non-toxic and compatible with the ingredients used in the composition. Suitable propellants are butane, isobutane, propane, dimethyl ether, dichlorodifluoromethane, tetrafluoromethane, dichlorotetrafluoroethane, chlorodifluoromethane, chlorodifluoroethane, difluoroethane, and mixtures thereof.
  • the preferred propellant of the present invention is a blend of isobutane and propane, commonly known as A-46 propellant.
  • Propellant is present in the range about 3 wt.% to about 15 wt.% of the present invention. Preferably, the propellant is about 5 wt.% to about 9 wt.%.
  • composition of the present invention optionally can have water.
  • Water can be present in an amount up to about 80 wt.%, preferably, from 30 wt.% to 70 wt.% of water.
  • the present composition may additionally contain one or more emollients.
  • An emollient provides a softening or soothing effect on the skin surface and is generally considered safe for topical use. Emollients also help control the rate of evaporation and the tackiness of the composition.
  • Preferred emollients include mineral oil, lanolin oil, coconut oil, cocoa butter, olive oil, aloe extracts, jojoba oils, castor oil, fatty acids such as oleic and stearic, fatty alcohols such as cetyl and hexadecyl (ENJAY), diisopropyl adipate, hydroxybenzoate esters, benzoic acid esters of C 9 -C-1 5 alcohols, isononyl iso-nonanoate, alkanes such as mineral oil, silicones such as dimethyl polysiloxane, ethers such as polyoxypropylene butyl ethers and polyoxypropylene cetyl ethers, and C ⁇ 2 -C 15 alkyl benzoates, and mixtures thereof.
  • the most preferred emollients are hydroxybenzoate esters, aloe vera, C ⁇ 2 -C 15 alkyl benzoates, and mixtures thereof.
  • Emollient is present in an amount about 1 wt.% to about 20 wt.% of the total weight of the composition.
  • the preferred amount of emollient is about 2 wt.% to about 15 wt.%, and most preferrably about 4 wt.% to about 10 wt.%.
  • Humectants A moistening agent, such as a humectant, may be incorporated into the present invention. Suitable humectants include glycerin, polyethylene glycol, polypropylene glycol, sorbitol, PEG-4, and mixtures thereof.
  • One or more humectants are optionally present at about 0.5 wt.% to about 8 wt.% in the present invention. Preferably, about 1 wt.% to about 5 wt.% of humectants may be used.
  • titanium dioxide may be added to the composition of the present invention.
  • This material is generally considered safe for topical use since it is physiologically inert and has a low degree of irritation and toxicity. It functions by reflecting and absorbing sunlight.
  • the titanium dioxide is suspended throughout the composition.
  • composition of the present invention may have about 0.5 wt.% to about 10 wt.% of titanium dioxide. Preferably, there is present about 1 wt.% to about 3 wt.% titanium dioxide.
  • preservatives/antioxidants may be in the present composition.
  • Diazolidinyl urea, iodopropynyl butylcarbamate, vitamin E, vitamin E acetate, vitamin C, butylated hydroxytoluene, methylparaben, and mixtures thereof may be a preservative/antioxidant in the present composition.
  • One or more preservatives/antioxidants may be present in an amount about 0.01 wt.% to about 2 wt.% of the total weight of the present invention. Preferably, one or more preservatives/antioxidants are present in an amount about 0.1 wt.% to about 1 wt.%.
  • the present invention may include a rheological additive, such as magnesium aluminum silicate, hydroxypropyl cellulose, carbomer, cellulose, guar gum, xanthan gum, bentonite, acrylate copolymers, and mixtures thereof.
  • a rheological additive such as magnesium aluminum silicate, hydroxypropyl cellulose, carbomer, cellulose, guar gum, xanthan gum, bentonite, acrylate copolymers, and mixtures thereof.
  • the rheological additive assists in building the viscosity of the present invention.
  • the rheological additive may optionally be present at about 0.05 wt.% to about 5 wt.% in the composition of the present invention.
  • rheological additives Preferably, about 0.1 wt.% to about 2 wt.% of rheological additives are present in the present composition.
  • the sunscreen composition of the present invention may also contain optional additives.
  • optional additives for instance, a fragrance, colorant, plant extract, absorbent, waterproofing agent, and mixtures thereof may be included.
  • the process used to manufacture the present invention must be capable of forming a homogeneous composition that can be sprayed or dispensed from an aerosol can.
  • aerosol products are made by filling a concentrate into a can and then filling the can with propellant under vacuum conditions.
  • the concentrate of the present invention may be prepared by using techniques and methods well known in the art. In general, ingredients are incorporated by mixing and applying heat if necessary, until the concentrate is uniform and homogeneous. If necessary, the concentrate may be homogenized to ensure homogeneity. The concentrate is then placed in an aerosol can which is later filled with propellant.

Abstract

The present invention is a sunscreen composition in the form of an aerosol that foams. The composition contains a sunscreen agent, an emulsifier, a foam builder/stabilizer, a counterion, and a propellant. In addition, the ratio of the foam builder/stabilizer to counterion is about 1:4 to about 5:1.2 to ensure the foam quality and integrity.

Description

SUNSCREEN AEROSOL COMPOSITION
BACKGROUND OF THE INVENTION
I. Field of the Invention The present invention relates to sunscreens. More particularly, the present invention relates to sunscreen compositions dispensed in the form of an aerosol product that foams.
II. Description of the Prior Art Sunscreen compositions are applied to the skin to protect the skin from the sun's ultraviolet rays that can lead to erythema, a reddening of the skin also known as sunburn. Sunlight or ultraviolet radiation in the UV-B range has a wavelength of 290nm to 320nm and is known to be the primary cause of sunburn. Ultraviolet rays at a wavelength of 320nm to 400nm, known as UV-A radiation, produces tanning of the skin. However, in the process of doing so, the UV-A rays can damage or harm the skin.
Besides the immediate malady of sunburn, excessive sunlight exposure can lead to skin disorders. For instance, prolonged and constant exposure to the sun may lead to actinic keratoses and carcinomas.
Another long-term effect is premature aging of the skin. This condition is characterized by skin that is wrinkled, cracked and has lost its elasticity.
As stated above, sunscreens are typically formulated with the goal of inhibiting skin damage from the sun's rays. The sunscreen composition filters or blocks the harmful UV-A and UV-B rays that can damage and harm the skin. It is believed that sunscreen agents accomplish this by absorbing the UV-A and/or UV-B rays.
In general, sunscreen compositions are oil and water emulsions. In this system, the UV-absorbing compounds are typically incorporated into the oil phase. Sunscreens may also include physical or inorganic metal oxides that block the sun's rays. Titanium dioxide and zinc oxide are commonly used for this purpose.
Consumers consider many factors when purchasing a sunscreen product. One of the most important considerations is the sun protection factor (SPF). This determines the amount of protection that the sunscreen composition provides over a given period of time. There are many to choose from and selection will be based upon the consumer's needs. The consumer also gives consideration to the substantivity of the product, that is how durable is the product after applying it over the skin. This effects how often the composition will need to be applied when the consumer is out in the sun. A third consideration is product feel and how well the product spreads over the skin. Typically, consumers want a product that feels smooth and silky and be applied in a smooth continuous film over the skin. Another factor is the shelf life of the product, which is determined by the chemical and physical stability of the sunscreen composition. In addition, product form will also play a part since there is a variety of choices such as lotions, gels, creams, sprays, and aerosols that are available. Form preference could ultimately determine whether the consumer decides to purchase the product.
The unique product forms can be appealing to many consumers who are looking for something different. Sunscreens that are made in the form of an aerosol are not commonplace, particularly, aerosols that deliver the product as a foam.
BRIEF SUMMARY OF THE INVENTION
It is an object of the present invention to provide a sunscreen composition that is dispensed as an aerosol product in the form of a foam.
It is also an object of the present invention to provide such a sunscreen composition that delivers superior foam quality. It is another object of the present invention to provide such a sunscreen composition that is effective in protecting the skin against UV-A and UV-B rays.
It is still another object of the present invention to provide such a sunscreen composition that spreads uniformly over the skin.
To accomplish the foregoing objects and advantages, the present invention, in brief summary, is a sunscreen composition that is dispensed as an aerosol product. The composition contains a sunscreen agent, an emulsifier, a foam builder/stabilizer, a counterion, and a propellant. In a preferred embodiment, the sunscreen composition also contains an emollient, a humectant, a preservative/antioxidant, and water.
Furthermore, the ratio of the foam builder/stabilizer to counterion must be about 1 :4 to about 5:1.2. More preferably, the ratio is about 1 :1 to about 5:1.
DETAILED DESCRIPTION OF THE INVENTION The present invention is a sunscreen composition in the form of an aerosol comprising a sunscreen agent, an emulsifier, a foam builder/stabilizer, a counterion, and a propellant.
Sunscreen agents The sunscreen agents that can be used in the present invention must be capable of absorbing or blocking the harmful effects of ultraviolet radiation. In addition, they must be non-toxic and non-irritating when applied to the skin. Suitable sunscreen agents include, for example, para- aminobenzoic acid (PABA), benzophenone-1 , benzophenone-2, benzophenone-3, benzophenone-4, benzophenone-6, benzophenone-8, benzophenone-12, methoxycinnamate, ethyl dihydroxypropyl-PABA, glyceryl PABA, homosalate, methyl anthranilate, octocrylene, octyl dimethyl PABA, octyl methoxycinnamate, octyl salicylate, PABA, 2- phenylbenzimidazole-5-sulphonic acid, triethanolamine salicylate, 3-(4- methylbenzylidene)-camphor, red petrolatum, and mixtures thereof. The preferred sunscreen agents are octyl methoxycinnamate, octyl salicylate, benzophenone-3, and mixtures thereof.
The sunscreen agents may be present in an amount about 1 wt.% to about 40 wt.% of the total weight of the composition of the present invention. The total amount of sunscreen agents in the composition will depend upon the sun protection factor (SPF) desired. Normally, the higher the SPF, the greater the total amount of sunscreen agents. Preferably, the sunscreen agents are included at about 4 wt.% to about 30 wt.%.
Emulsifiers
An emulsifier is an essential component of the present invention. An emulsifier enables two or more immiscible liquids to be combined homogeneously, while increasing the viscosity of the composition.
Moreover, the emulsifier acts to stabilize the composition. Emulsifiers that may be used in the present invention include sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate, sorbitan trioleate, polyglyceryl-3- diisostearate, polyglycerol esters of oleic/isostearic acid, polyglyceryl-6 hexaricinolate, polyglyceryl-4-oleate, polygylceryl-4 oleate/PEG-8 propylene glycol cocoate, oleamide DEA, sodium glyceryl oleate phosphate, hydrogenated vegetable glycerides phosphate and mixtures thereof.
Furthermore, one or more synthetic polymers may be used as an emulsifier. For example, PVP Eicosene copolymer, acrylat.es/C-io-C30 alkyl acrylate crosspolymer, acrylates/steareth-20 methacrylate copolymer, PEG-22/dodecyl glycol copolymer, PEG-45/dodecyl glycol copolymer, and mixtures thereof.
The preferred emulsifiers are PVP Eicosene copolymer, acrylates/C10-C3o alkyl acrylate crosspolymer, PEG-20 sorbitan isostearate, sorbitan isostearate, and mixtures thereof. The one or more emulsifiers are present in a total amount about 0.01 wt.% to about 15 wt.% of the total weight of the composition of the present invention. Preferably, about 0.1 wt.% to about 3 wt.% of emulsifiers are used.
Foam Builder/Stabilizer
The composition of the present invention must include a foam builder/stabilizer. The preferred foam builder/stabilizer is cetyl phosphate, DEA cetyl phosphate, TEA myristate, TEA stearate, magnesium stearate, sodium stearate, potassium laurate, potassium ricinoleate, sodium cocoate, sodium tallowate, potassium castorate, sodium oleate, and mixtures thereof. The foam builder/stabilizer in an amount about 0.1 wt.% to about 5 wt.% must be added to the composition of the present invention. Preferably, the foam builder/stabilizer is present in an amount about 0.1 wt.% to about 3 wt.%.
Counterions
Counterions are in the composition of the present invention to neutralize components such as an emulsifier and a foam builders/stabilizer. Sodium hydroxide, potassium hydroxide, diethanolamine, triethanolamine, aminomethyl propanol, trisodium ethylenediaminetetraacetic acid, and mixtures thereof, are examples of suitable counterions used in the present invention. The preferred counterion is triethanolamine.
Counterion is present in an amount about 0.01 wt.% to about 8 wt.% in the composition of the present invention. Preferably, counterion is present in an amount about 1 wt.% to about 5 wt.%.
A critical feature of the present invention is the ratio of the foam builder/stabilizer to counterion. To ensure superior foam quality and integrity, the ratio must be about 1 :4 to about 5:1.2. Preferably, the ratio is about 1 :1 to about 5:1.
Propellant The propellant must be capable of producing a sufficient pressure for expelling the composition from an aerosol container. Furthermore, the propellant must be non-irritating, non-toxic and compatible with the ingredients used in the composition. Suitable propellants are butane, isobutane, propane, dimethyl ether, dichlorodifluoromethane, tetrafluoromethane, dichlorotetrafluoroethane, chlorodifluoromethane, chlorodifluoroethane, difluoroethane, and mixtures thereof. The preferred propellant of the present invention is a blend of isobutane and propane, commonly known as A-46 propellant. Propellant is present in the range about 3 wt.% to about 15 wt.% of the present invention. Preferably, the propellant is about 5 wt.% to about 9 wt.%.
Water
The composition of the present invention optionally can have water. Water can be present in an amount up to about 80 wt.%, preferably, from 30 wt.% to 70 wt.% of water.
Emollients
The present composition may additionally contain one or more emollients. An emollient provides a softening or soothing effect on the skin surface and is generally considered safe for topical use. Emollients also help control the rate of evaporation and the tackiness of the composition. Preferred emollients include mineral oil, lanolin oil, coconut oil, cocoa butter, olive oil, aloe extracts, jojoba oils, castor oil, fatty acids such as oleic and stearic, fatty alcohols such as cetyl and hexadecyl (ENJAY), diisopropyl adipate, hydroxybenzoate esters, benzoic acid esters of C9-C-15 alcohols, isononyl iso-nonanoate, alkanes such as mineral oil, silicones such as dimethyl polysiloxane, ethers such as polyoxypropylene butyl ethers and polyoxypropylene cetyl ethers, and Cι2-C15 alkyl benzoates, and mixtures thereof. The most preferred emollients are hydroxybenzoate esters, aloe vera, Cι2-C15 alkyl benzoates, and mixtures thereof.
Emollient is present in an amount about 1 wt.% to about 20 wt.% of the total weight of the composition. The preferred amount of emollient is about 2 wt.% to about 15 wt.%, and most preferrably about 4 wt.% to about 10 wt.%.
Humectants A moistening agent, such as a humectant, may be incorporated into the present invention. Suitable humectants include glycerin, polyethylene glycol, polypropylene glycol, sorbitol, PEG-4, and mixtures thereof.
One or more humectants are optionally present at about 0.5 wt.% to about 8 wt.% in the present invention. Preferably, about 1 wt.% to about 5 wt.% of humectants may be used.
Titanium dioxide
Optionally, titanium dioxide may be added to the composition of the present invention. This material is generally considered safe for topical use since it is physiologically inert and has a low degree of irritation and toxicity. It functions by reflecting and absorbing sunlight. In the present invention, the titanium dioxide is suspended throughout the composition.
The composition of the present invention may have about 0.5 wt.% to about 10 wt.% of titanium dioxide. Preferably, there is present about 1 wt.% to about 3 wt.% titanium dioxide.
Preservatives/Antioxidants Optionally, preservatives/antioxidants may be in the present composition. Diazolidinyl urea, iodopropynyl butylcarbamate, vitamin E, vitamin E acetate, vitamin C, butylated hydroxytoluene, methylparaben, and mixtures thereof may be a preservative/antioxidant in the present composition.
One or more preservatives/antioxidants may be present in an amount about 0.01 wt.% to about 2 wt.% of the total weight of the present invention. Preferably, one or more preservatives/antioxidants are present in an amount about 0.1 wt.% to about 1 wt.%. Rheological Additives
The present invention may include a rheological additive, such as magnesium aluminum silicate, hydroxypropyl cellulose, carbomer, cellulose, guar gum, xanthan gum, bentonite, acrylate copolymers, and mixtures thereof. The rheological additive assists in building the viscosity of the present invention.
The rheological additive may optionally be present at about 0.05 wt.% to about 5 wt.% in the composition of the present invention.
Preferably, about 0.1 wt.% to about 2 wt.% of rheological additives are present in the present composition.
Optional Additives The sunscreen composition of the present invention may also contain optional additives. For instance, a fragrance, colorant, plant extract, absorbent, waterproofing agent, and mixtures thereof may be included.
Process
The process used to manufacture the present invention must be capable of forming a homogeneous composition that can be sprayed or dispensed from an aerosol can.
Typically, aerosol products are made by filling a concentrate into a can and then filling the can with propellant under vacuum conditions.
The concentrate of the present invention may be prepared by using techniques and methods well known in the art. In general, ingredients are incorporated by mixing and applying heat if necessary, until the concentrate is uniform and homogeneous. If necessary, the concentrate may be homogenized to ensure homogeneity. The concentrate is then placed in an aerosol can which is later filled with propellant.
Having thus described the present invention with particular reference to preferred embodiments thereof, it will be apparent that various changes and modifications may be made therein without departing from the spirit and scope of the invention as defined in the appended claims.

Claims

WHAT IS CLAIMED IS:
1. A sunscreen composition comprising:
(a) a sunscreen agent; (b) an emulsifier;
(c) a foam builder/stabilizer;
(d) a counterion; and
(e) a propellant.
2. The composition of claim 1 , wherein said ratio of foam builder/stabilizer to said counterion is about 1 :4 to about 5:1.2.
3. The composition of claim 1 , wherein said foam builder/stabilizer is selected from the group consisting of cetyl phosphate, DEA cetyl phosphate, sodium stearate, potassium ricinoleate, sodium tallowate, and mixtures thereof.
4. The composition of claim 1 , wherein said foam builder/stabilizer is about 0.1 wt.% to about 5 wt.% of the total weight of the composition.
5. The composition of claim 1 , wherein said counterion is selected from the group consisting of sodium hydroxide, potassium hydroxide, diethanolamine, triethanolamine, aminomethyl propanol, trisodium ethylenediaminetetraacetic acid, and mixtures thereof.
6. The composition of claim 1 , wherein said counterion is about 0.01 wt.% to about 8 wt.% of the total weight of the composition.
7. The composition of claim 1 , wherein said sunscreen agent is about 4 wt.% to about 30 wt.% of the total weight of the composition.
8. The composition of claim 7, wherein said sunscreen agent is selected from the group consisting of benzophenoπe-3, octyl methoxycinnamate, octyl salicylate, homosalate, and mixtures thereof.
9. The composition of claim 1 , wherein said emulsifier is about
0.01 wt.% to about 15 wt.% of the total weight of the composition.
10. The composition of claim 9, wherein said emulsifier is selected from the group consisting of PVP Eicosene copolymer, sorbitan isostearate, acrylates/C^-Cso alkyl acrylate crosspolymer, PEG-20 sorbitan isostearate, and mixtures thereof.
11. The composition of claim 1 , wherein said propellant is a blend of isobutane and propane.
12. The composition of claim 1 , further comprising water.
13. The composition of claim 1 , further comprising an emollient.
14. The composition of claim 13, wherein said emollient is selected from the group consisting of hydroxybenzoate esters, Cι2-C15 alkyl benzoates, aloe vera, and mixtures thereof.
15. The composition of claim 1 , further comprising a humectant.
16. The composition of claim 15, wherein said humectant is PEG-
4.
17. The composition of claim 1 , further comprising titanium dioxide.
18. The composition of claim 1 , further comprising a rheological additive. 01/05366
12
19. The composition of claim 18, wherein said rheological additive is magnesium aluminum silicate.
20. The composition of claim 1 , further comprising a preservative/antioxidant.
21. The composition of claim 20, wherein said preservative/antioxidant is selected from the group consisting of diazolidinyl urea, iodopropynyl butylcarbamate, vitamin E, vitamin E acetate, vitamin C, butylated hydroxytoluene, methylparaben, and mixtures thereof.
22. The composition of claim 1 , further comprising optional ingredients selected from the group consisting of a fragrance, colorant, plant extract, absorbent, waterproofing agent, and mixtures thereof.
PCT/US2000/019459 1999-07-15 2000-07-14 Sunscreen aerosol composition WO2001005366A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00947462A EP1200054A1 (en) 1999-07-15 2000-07-14 Sunscreen aerosol composition
MXPA02000457A MXPA02000457A (en) 1999-07-15 2000-07-14 Sunscreen aerosol composition.
AU61065/00A AU6106500A (en) 1999-07-15 2000-07-14 Sunscreen aerosol composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14426499P 1999-07-15 1999-07-15
US60/144,264 1999-07-15

Publications (1)

Publication Number Publication Date
WO2001005366A1 true WO2001005366A1 (en) 2001-01-25

Family

ID=22507819

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/019459 WO2001005366A1 (en) 1999-07-15 2000-07-14 Sunscreen aerosol composition

Country Status (5)

Country Link
EP (1) EP1200054A1 (en)
AU (1) AU6106500A (en)
CA (1) CA2313955A1 (en)
MX (1) MXPA02000457A (en)
WO (1) WO2001005366A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011238A2 (en) * 2001-07-31 2003-02-13 Merck Patent Gmbh Sunscreen composition
KR20030013945A (en) * 2001-08-10 2003-02-15 이인혜 Process for preparing a spray type sunscreen agent
WO2004071479A1 (en) * 2003-02-12 2004-08-26 Connetics Australia Pty Ltd Film foaming hydroalcoholic foam
WO2006099687A1 (en) * 2005-03-24 2006-09-28 Ensign Laboratories Pty Ltd Sunscreen aerosol spray
WO2007002047A1 (en) * 2005-06-20 2007-01-04 The Procter & Gamble Company A product release system to atomize cosmetic hair or skin compositions containing uv filters
US8173108B2 (en) 2009-11-04 2012-05-08 Conopco, Inc. Sunscreen composition
US8206691B2 (en) 2009-11-04 2012-06-26 Conopco, Inc. Sunscreen composition with fatty acid alkanolamides
US8841778B2 (en) 1997-04-04 2014-09-23 Glenn J Leedy Three dimensional memory structure
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0791353A1 (en) * 1996-02-26 1997-08-27 Shiseido Company Limited Ultraviolet absorbing composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0791353A1 (en) * 1996-02-26 1997-08-27 Shiseido Company Limited Ultraviolet absorbing composition

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841778B2 (en) 1997-04-04 2014-09-23 Glenn J Leedy Three dimensional memory structure
US8907499B2 (en) 1997-04-04 2014-12-09 Glenn J Leedy Three dimensional structure memory
WO2003011238A3 (en) * 2001-07-31 2003-08-28 Merck Patent Gmbh Sunscreen composition
WO2003011238A2 (en) * 2001-07-31 2003-02-13 Merck Patent Gmbh Sunscreen composition
KR20030013945A (en) * 2001-08-10 2003-02-15 이인혜 Process for preparing a spray type sunscreen agent
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
WO2004071479A1 (en) * 2003-02-12 2004-08-26 Connetics Australia Pty Ltd Film foaming hydroalcoholic foam
US8562959B2 (en) 2003-02-12 2013-10-22 Stiefel Research Australia Pty Ltd Film foaming hydroalcoholic foam
US9211237B2 (en) 2003-02-12 2015-12-15 Stiefel Research Australia Pty Ltd Film foaming hydroalcoholic foam
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
WO2006099687A1 (en) * 2005-03-24 2006-09-28 Ensign Laboratories Pty Ltd Sunscreen aerosol spray
WO2007002047A1 (en) * 2005-06-20 2007-01-04 The Procter & Gamble Company A product release system to atomize cosmetic hair or skin compositions containing uv filters
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US8992896B2 (en) 2009-10-02 2015-03-31 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10946101B2 (en) 2009-10-02 2021-03-16 Vyne Therapeutics Inc. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
US8206691B2 (en) 2009-11-04 2012-06-26 Conopco, Inc. Sunscreen composition with fatty acid alkanolamides
US8173108B2 (en) 2009-11-04 2012-05-08 Conopco, Inc. Sunscreen composition
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne

Also Published As

Publication number Publication date
AU6106500A (en) 2001-02-05
MXPA02000457A (en) 2002-07-30
EP1200054A1 (en) 2002-05-02
CA2313955A1 (en) 2001-01-15

Similar Documents

Publication Publication Date Title
EP1200054A1 (en) Sunscreen aerosol composition
US6395269B1 (en) Sunscreen lotion or spray composition
US6190645B1 (en) Sunscreen for the scalp hair and hair
CA2461126C (en) Sunscreen compositions
AU2003237369B8 (en) Sunscreen compositions
EP1594454B1 (en) Film forming hydroalcoholic foam
EP1866033B1 (en) Sunscreen aerosol spray
AU2002336539A1 (en) Sunscreen compositions
US6146618A (en) Disappearing color sunscreen compositions
CA2526626C (en) Emulsion base for skin care compositions
US5989529A (en) Substantive topical composition
JP3749548B2 (en) High SPF sunscreen formulation
US5208011A (en) Ultraviolet resistant sunscreen compositions
WO2002043490A1 (en) Foaming insect repellent compositions
AU671189B2 (en) Sunscreen compositions
JP2011506610A (en) Enhanced photostabilization of abozenzone using phosphate-based emulsifiers in the presence of zinc oxide
JP2006001930A (en) Skin care composition
CN114630651B (en) Sunscreen compositions with low tack
MXPA02001664A (en) Sunscreen lotion or spray composition
CN117320687A (en) Sun protection composition containing Bei Mo triazinyl alcohol
AU2006227561A1 (en) Sunscreen aerosol spray

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/000457

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000947462

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000947462

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000947462

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP